Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Pertuzumab in HER2+ Esophageal Cancer
NCT05188313Phase 3Recruiting
- Sponsor
- University of Amsterdam
- Start
- Mar 2022
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab, pertuzumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by University of Amsterdam. Started Mar 2022; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05188313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188313.